Measuring agreement between diagnostic devices – sleep apnea monitoring

W. Ward Flemons

There is growing interest in using portable monitoring for investigating patients with suspected sleep apnea. Research studies typically report portable monitoring results in comparison with the results of sleep laboratory-based polysomnography. A systematic review of this research has recently been completed by a joint working group of the American College of Chest Physicians, the American Thoracic Society, and the American Academy of Sleep Medicine. The methods for comparing the results of portable monitors and polysomnography include product-moment correlation, intraclass correlation, mean differences/limits of agreement, sensitivity, specificity, and likelihood ratios. Each approach has advantages and limitations, which are highlighted in this review.

Key words: diagnosis; likelihood ratios: methods; polysomnography; research design; sensitivity and specificity; sleep apnea syndromes

Abbreviations: AHI = apnea-hypopnea index; LR = likelihood ratio; RDI = respiratory disturbance index; ROC = receiver operating characteristic

**********

The recommended method for diagnosing sleep apnea is polysomnography.(1) As physicians and the general population have gained awareness of sleep apnea, there has been a steadily increasing demand for the investigation of patients who are suspected of having this disorder, which in many sleep laboratories has resulted in unacceptably long waiting lists. This problem has prompted increasing interest in other possible diagnostic approaches, the most common of which is some type of portable monitoring that does not require the patient to be studied in a sleep laboratory. Typically, these devices have utilized various combinations of signals that are commonly used during polysomnography, such as oximetry alone, airflow measured by thermistor or nasal pressure, heart rate variation, snoring, or ribcage/abdominal movement. Some monitors have continued to use EEG and electromyogram recording that allows for sleep staging and the calculation of an apnea-hypopnea index (AHI) [ie, the total number of apneas and hypopneas per hour of sleep time], but the majority do not. Instead, they quantitate “respiratory disturbances” (not distinguishing between apneas and hypopneas) and use total monitoring time as the quotient to determine the respiratory disturbance index (RDI). The validity of portable monitors for investigating patients with suspected sleep apnea generally has been studied by comparing their results with those of the accepted reference standard, sleep-laboratory based polysomnography. A systematic review of the research evidence on portable monitoring for investigating patients with suspected sleep apnea has been conducted by a joint working group of the American College of Chest Physicians, the American Thoracic Society, and the American Academy of Sleep Medicine using the principles outlined in this methodology review (see page 1543).

There are several commonly used approaches for assessing how well two different methods, which have been designed to measure a common variable such as breathing disturbances during sleep, agree with each other. Each method has its strengths and weaknesses. Pearson product-moment correlation coefficients have as an advantage over other methods that they are in common use and that the scale is easily understood. However, they can be misleading and therefore are not recommended.(2) Intraclass correlation coefficients compare total variability among patients, measurement variability and measurement error.(3) Statistically, they are superior to product-moment correlation coefficients. However, this approach is not intuitive to clinicians and is not commonly used. Calculating the mean differences between two methods of measurement is useful and is preferable to correlation. However, the limits of agreement, the key descriptor that relates how well the measures agree, can be misleading if not calculated properly.

Ultimately, a clinician could accept that the measurement of breathing events using a portable monitor does not agree completely with polysomnography as long as it classifies patients accurately as those with and those without sleep apnea. For these purposes, using sensitivity, specificity, and likelihood ratios (LRs) is more appealing. However, this approach dictates that a patient be classified as having or not having the disorder based on an arbitrary cutoff for the AHI that is variable across studies. There is a wide spectrum of severity of breathing events at night, and the AHI captures only a single dimension. Since a large number of patients have index values around the usual cutoff point, it is possible that a patient’s classification could change due to expected variability in the measurement. By dichotomizing results into simply positive or negative, a substantial proportion of information is lost, in particular, information that could better classify a patient as having mild, moderate, or severe disease.

CORRELATION ANALYSIS

Measuring agreement between two different clinical measurements using a product-moment correlation coefficient can be misleading, since it is only a measure of the strength of a relation. Two methods may correlate perfectly but have different scales of measurement, in which ease they do not agree. Furthermore, this type of correlation depends on the range of values that are being compared (the wider the range, the stronger the correlation), yet this does not necessarily reflect greater agreement between two methods. For these reasons product-moment correlation coefficients are not recommended as a statistic to describe how well two methods of measurement agree. (2) A hypothetical example of the comparison between the RDI measured by a portable monitor and the AHI determined from polysomnography is shown in Figure 1. The product-moment correlation coefficient is high (r = 0.83), highly statistically significant, and would suggest that the two methods have excellent agreement. However, this correlation coefficient is able to indicate only that the two measurements are related.

[FIGURE 1 OMITTED]

MEAN DIFFERENCE AND LIMITS OF AGREEMENT (BLAND-ALTMAN)

A widely accepted method of measuring agreement is the approach proposed by Bland and Altman(2) in which the difference between the two measurements for each subject is determined. The mean difference provides an estimate of whether the two methods, on average, return a similar result. A mean difference other than 0 suggests a systematic bias in the way that one method is measuring the clinical result of interest (eg, the RDI). The measure of agreement is based on calculating the SDs of the mean difference. The limits of agreement have been defined as [+ or -] 2 SDs. How far apart these limits of agreement should be for a measurement method is a question of judgment. Some authors calculate 95% confidence intervals of the estimate of the mean difference and report this rather than the limits of agreement. The two values are related but are not the stone. The limits of agreement will be larger. Figure 2 plots the same data that are presented in Figure 1. Each data point represents the difference between the RDI and the AHI for an individual patient. This is plotted against the average value (ie, RDI + AHI/2) for each patient. With this presentation of the data, it is easy to observe that the mean difference is approximately 7.6 (indicating a systematic bias) and that the limits of agreement are wide (ie, discrepancies of up to 28 events per hour), indicating that there is a substantial lack of agreement.

The limits of agreement may be misleading in the Case in which the difference between measurements varies in a systematic way over the range of measurements.(3) A comparison of measurements of breathing disturbances often shows larger differences as the AHI increases. This results in limits of agreement that are too wide for small values of the AHI and are not wide enough for higher values. Therefore, the use of a logarithmic transformation of differences between polysomnography and portable monitors is recommended, but this is rarely done in practice. When it is not done, the quoted limits of agreement can be misleading and should be interpreted with caution.

[FIGURE 2 OMITTED]

SENSITIVITY/SPECIFICITY

The operating characteristics of tests are often summarized as sensitivity (ie, the proportion of patients with disease who have a positive test result, or the true-positive rate) and specificity (ie, the proportion of patients without disease who have a negative result, or the true-negative rate). Using sensitivity and specificity to describe the utility of a diagnostic test has some limitations, since they indicate the probability that the test result will be positive if the patient has the disease, and the probability that the test will be negative if the patient does not have the disease. Clinicians cannot apply these numbers directly, because they do not know whether or not the patient has the disease. What the physician wants to know is conditional, the probability that the patient has the disease if the test is positive or negative (ie, the positive and negative predictive values of the test, respectively). Sensitivity and specificity can be determined by analyzing the columns in a 2 x 2 table (Table 1), while the positive and negative predictive values are obtained by analyzing the rows. By convention, the reference standard is at the top and the new diagnostic test that is being compared to it is on the side. For sleep apnea, the reference standard is a definition of sleep apnea based on the AHI (the most common cutoffs used are 10 or 15), and the diagnostic test values are the result of the portable monitor. Sensitivity, specificity, prevalence (or pretest probability), and predictive values provide valuable information about a diagnostic test. However, it can be a challenge to interpret several different numbers that all describe the operating characteristics and outcomes of a test.

In the first example in Table 1, if the diagnostic test was being used to exclude sleep apnea, 81% of the tests would be negative and only 10 of 810 of those negative test results (or 1%) would be false-negative. If the test was being used to confirm a diagnosis of sleep apnea, only 19% of the tests would be positive, and of those testing positive, more than half (53%) would be false-positive. If the stone test was used in the second example in Table 1, in which the prevalence (ie, pretest probability) is much higher, the number of negative results would be much lower (49.5%), and the percentage of false-positive results would rise to 10%. However, in the second example in Table 1 the test would have more usefulness to rule in the disorder (patients testing positive, 50.5%; false-positive results, 11% [of those testing positive]).

When two methods of measurement do not completely agree, the potential user of the test should understand the interaction of sensitivity, specificity, and pretest probability that will dictate the number of tests that will, on average, come back positive or negative and the percentage of times that a positive result will be false-positive, and a negative result will be false-negative. The thresholds of sensitivity and specificity that dictate the ability’ of a test to exclude or confirm a diagnosis in a substantial percentage of cases and the acceptable rate of false results will be affected by several factors, such as the potential risk to a patient of having test results being labeled false-negative or false-positive. In the former ease, it could potentially deny the patient a trial of beneficial therapy. However, this risk could be reduced if symptomatic patients were offered a second test or a polysomnogram. In the latter case, the patient may be offered a trial of therapy in circumstances in which it may not otherwise be indicated. The risk associated with this in sleep apnea is likely to be small, but unless the trial was conducted with polysomnography, it would be difficult to determine whether the use was warranted.

Changing the threshold of what constitutes a normal or abnormal diagnostic test result will change the sensitivity and specificity. Lowering the threshold will increase sensitivity but lower specificity, resulting in more true-positive results (and therefore fewer false-negative results) but also in more false-positive results (and fewer false-negative results). The converse (ie, increasing the threshold) will have the opposite effect (ie, lower sensitivity and increased specificity). A threshold that results in a low false-negative rate (ie, high sensitivity) is useful to exclude disease, but very few patients may actually have a negative result, so, practically, the impact of performing the test on a population of patients may be small. The converse is true for setting the threshold of a test quite high in order to improve specificity. Very few patients actually may receive a positive result. A receiver operating characteristic (ROC) curve often is used to illustrate the effect of changing thresholds for a positive diagnostic test result (Fig 3).

[FIGURE 3 OMITTED]

LRs

Although sensitivity and specificity are more likely to be used to infer the utility of a diagnostic test to exclude or confirm a disease, either of these statistics, when considered in isolation, can be misleading. This is because positive and negative predictive values depend on the combination of sensitivity and specificity. The utility of a test for excluding or confirming a disorder can be captured in a single number, the LB. The LR for a positive test result is the ratio of the proportion of patients with disease who have a positive test result (ie, the true-positive rate or sensitivity) to the proportion of people without disease who have a positive test result (ie, the false-positive rate). (4) Similarly, the LR for a negative test result is the ratio of the proportion of patients with disease who have a negative test result (ie, the false-negative rate) to the proportion of people without disease who have a negative test result (ie, the true-negative rate or specificity). Using the example of the 2 x 2 table in the first example ill Table 1, the LR for a positive result is calculated as 0.90/0.11 = 8.1. The LR for a negative result is calculated as 0.10/0.89 = 0.11. Mathematically, when using LRs to convert pretest to posttest probabilities, the pretest probability estimate (ie, the estimated prevalence) is first converted to an odds expression (ie, pretest odds = pretest probability/ 1–pretest probability), then is multiplied by the LR to obtain the posttest odds, which then are converted back to a probability statement (ie, posttest probability = posttest odds/posttest odds + 1). This process can be greatly simplified with the use of a nomogram (Fig 4). (5) The nomogram and Table 2 also highlight the interaction between pretest probability and LR on posttest probability. Of note, the posttest probabilities are equal to the positive predictive value and 100 minus the negative predictive value (expressed as the percentages).

[FIGURE 4 OMITTED]

The LR in a single number captures the utility of a test to change the probability of disease, and therefore is recommended over sensitivity and specificity for this purpose. The relationship of LRs to different combinations of sensitivity and specificity is shown in Table 3. A guide to the interpretation of LRs is given as follows: 20.0, very, large increase.

EVALUATING MULTIPLE THRESHOLD VALUES FOR BEST SENSITIVITY AND BEST SPECIFICITY

When trying to address the issue of whether a portable monitor can reduce the probability that a patient has sleep apnea, the focus is on sensitivity. A high sensitivity will result in a low number of false-negative results and a low LR. Conversely, when addressing the issue of whether a portable monitor can increase the probability of sleep apnea, the focus is on specificity. A high specificity will result in a high LR and a low number of false-positive results.

When the best sensitivity and the best specificity are at different RDI thresholds (ie, different points on the ROC curve), then some patients will meet one or the other criteria, but some will meet neither and therefore will have indeterminate results. For example, if authors reported their best sensitivity at an RDI cutoff of 5 and their best specificity at an RDI cutoff of 15, those patients whose RDI fell between these two thresholds would have a result that did not substantially reduce or increase the probability that they had sleep apnea. If the results are such that a majority of patients fall into this “gray zone,” then the test may not be as useful as the best sensitivity and best specificity might suggest. In this regard, it is useful to examine the percentage of patients who meet the criteria for a negative result (ie, best sensitivity) and the percentage that meet the criteria for a positive result (ie, best specificity). Once it is clear what percentage of patients meets the criteria for a negative result or a positive result, the final important questions is what percentage of those patients meeting the criteria actually had a false result (ie, were misclassified by the diagnostic test). This result will be affected by the prevalence as well as the operating characteristics of the test (ie, sensitivity, specificity, and LRs). The best test obviously will be the one with the largest majority of patients who meet the criteria and have a low misclassification rate. The ideal test is one in which there is a single cutoff that has both a high sensitivity and high specificity, so that patients have either a negative or positive result, and there is no gray zone.

Using different thresholds for positive and negative results generates combinations of sensitivity and specificity, and different LRs that can be confusing. The example below illustrates this.

Example

Consider 1,000 patients who are suspected of having sleep apnea, 40% of whom ultimately have a positive polysomnogram finding (ie, AHI [greater than or equal to] 10). All patients have an RDI measured from a portable monitor, and the breakdown of the results is shown in Table 4. If the threshold for a positive result on the portable monitor is changed between the upper group (ie, AHI < 40 or [greater than or equal to] 40) and the lowest group (ie, < 5 or [greater than or equal to] 5), a series of 2 x 2 tables can be constructed to evaluate the effect on several different parameters (eg, sensitivity, specificity, predictive values, and percentage of patients with a positive or negative result). This is illustrated in Table 5.

When several thresholds are being evaluated for a diagnostic test, it is possible to calculate pairs of LRs for each level of the portable monitor result. However, it is more appropriate to calculate LRs for each intermediate threshold, as shown in Table 6, rather than calculating them for each pair (Table 5). Note that the only LRs that correspond between these two approaches are the LR for a positive result at the highest threshold and the LR for a negative result at the lowest threshold.

If separate thresholds are used to define a group of patients with sleep apnea and another group of patients without sleep apnea, some patients will fulfill neither criterion. The following tables give the approach used to calculate the number of patients without a positive or negative result. Table 7 combines best specificity (ie, RDI [greater than or equal to] 40) and the best sensitivity (ie, RDI < 5) [see Table 5 for corresponding calculations]. The outcome is that 462 patients do not have a positive or negative result (ie, they have an RDI between 5 and 40), and among 538 patients with a positive or negative result there are 13 false-negative results and 8 false-positive results.

Table 8 demonstrates the effect of using a lower RDI threshold to define patients with sleep apnea (ie, RDI [greater than or equal] 20) while maintaining the threshold for defining patients without disease (ie, RDI < 5). The choice of which set of RDIs to use depends on many factors such as the repercussions to the patient of false-positive or false-negative test results. In Table 8, there are more patients who have a positive or negative result (69.8%). There are still 13 false-negative results, but now the number of false-positive results has risen to 39. The difference is that 159 more patients now have a result, but among these 159 patients are 31 more false-positive results.

CONCLUSIONS

Although there are several approaches to measuring agreement between two methods of measurement, such as portable monitoring and polysomnography, each one has limitations. The two recommended approaches are the following: (1) the Bland-Altman calculation of mean differences mid limits of agreement; and (2) sensitivity, specificity, and LRs. The latter approach is in most common use. To correctly interpret the meaning of the combination of sensitivity and specificity or a LR, it is important to understand how test operating characteristics interact with pretest probability (ie, prevalence) to generate predictive values (posttest probabilities), which is the information that a clinician requires to make an informed choice about a diagnostic test. A test result above a threshold level that is associated with a high LR indicates an increased probability of disease. The higher the LR, the higher the probability. A test result below a threshold that is associated with a low LR indicates a decreased probability of disease. The lower the LR, the lower the probability. It is important to remember that when different thresholds are used to generate high and low LRs (or high specificities or sensitivities, respectively), a certain and possibly substantial proportion of patients may have a nondiagnostic result. This percentage should be considered when evaluating the utility of the test in a particular patient population.

Table 1–Calculating Sensitivity, Specificity, Positive

and Negative Predictive Values, and the Effect of

Prevalence *

RS

DT Positive Negative

10% prevalence ([dagger])

Positive 90 ([double dagger]) 100 ([section])

Negative 10 ([parallel]) 800 ([paragraph])

Total 100 900

50% prevalence (#)

Positive 450 55

Negative 50 445

Total 500 500

DT Total

10% prevalence ([dagger])

Positive 190

Negative 810

Total 1,000

50% prevalence (#)

Positive 505

Negative 495

Total 1,000

* DT = diagnostic test: RS = reference standard. TP = true-positive;

FP = false-positive; FN = false-negative; TN = true-negative.

Sensitivity = TP * 100/TP + FN; specificity = TN * 100/TN + FP;

positive predictive value = TP * 100/TP + FP; negative predictive

value = TN * 100/TN + FN.

([dagger]) In this hypothetical example, 90 of 100 patients who have a

disease (prevalence, 10%) defined by a positive RS test have a positive

diagnostic test (sensitivity, 90.0% and 800 of 900 of those who do

not have the disease have a negative test result (specificity, 88.9%).

The positive predictive value is 90/190 of 47.3%. The negative

predictive value is 800/810 or 98.8%.

([double dagger]) True-positive result.

([section]) False-positive result.

([parallel]) False-negative result.

([paragraph]) True-negative result.

(#) In this example, prevalence has increased to 50% with no change in

sensitivity or specificity. However, the positive predictive value has

increased substantially to 89.1%, and the negative predictive value has

dropped to 89.9%.

Table 2–Impact of Pretest Probability and LRs on

Posttest Probability

Pretest Posttest Posttest

Probability, % LR Odds Probability, %

10 0.05 0.01 0.6

10 0.1 0.01 1.1

10 0.2 0.02 2.2

10 0.4 0.04 4.3

10 0.7 0.08 7.2

10 2 0.22 18.2

10 5 0.56 35.7

10 10 1.11 52.6

10 20 2.22 69.0

20 0.05 0.01 1.2

20 0.1 0.03 2.4

20 0.2 0.05 4.8

20 0.4 0.10 9.1

20 0.7 0.18 14.9

20 2 0.50 33.3

20 5 1.25 55.6

20 10 2.50 71.4

20 20 5.00 83.3

30 0.05 0.02 2.1

30 0.1 0.04 4.1

30 0.2 0.09 7.9

30 0.4 0.17 14.6

30 0.7 0.30 23.1

30 2 0.86 46.2

30 5 2.14 68.2

30 10 4.29 81.1

30 20 8.57 89.6

40 0.05 0.03 3.2

40 0.1 0.07 6.3

40 0.2 0.13 11.8

40 0.4 0.27 21.1

40 0.7 0.47 31.8

40 2 1.33 57.1

40 5 3.33 76.9

40 10 6.67 87.0

40 20 13.33 93.0

50 0.05 0.05 4.8

50 0.1 0.10 9.1

50 0.2 0.20 16.7

50 0.4 0.40 28.6

50 0.7 0.70 41.2

50 2 2.00 66.7

50 5 5.00 83.3

50 10 10.00 90.9

50 20 20.00 95.2

60 0.05 0.08 7.0

60 0.1 0.15 13.0

60 0.2 0.30 23.1

60 0.4 0.60 37.5

60 0.7 1.05 51.2

60 2 3.00 75.0

60 5 7.50 88.2

60 10 15.00 93.8

60 20 30.00 96.8

70 0.05 0.12 10.4

70 0.1 0.23 18.9

70 0.2 0.47 31.8

70 0.4 0.93 48.3

70 0.7 1.63 62.0

70 2 4.67 82.4

70 5 11.67 92.1

70 10 23.33 95.9

70 20 46.67 97.9

80 0.05 0.20 16.7

80 0.1 0.40 28.6

80 0.2 0.80 44.4

80 0.4 1.60 61.5

80 0.7 2.80 73.7

80 2 8.00 88.9

80 5 20.00 95.2

80 10 40.00 97.6

80 20 80.00 98.8

90 0.05 0.45 31.0

90 0.1 0.90 47.4

90 0.2 1.80 64.3

90 0.4 3.60 78.3

90 0.7 6.30 86.3

90 2 18.00 94.7

90 5 45.00 97.8

90 10 90.00 98.9

90 20 180.00 99.4

Table 3–Combinations of Sensitivity and Specificity

with Corresponding Positive and Negative LRs *

LR

Sensitivity Specificity Pos Neg

98 98 49.0 0.02

98 95 19.6 0.02

98 90 9.8 0.02

98 85 6.5 0.02

98 80 4.9 0.03

98 75 3.9 0.03

98 70 3.3 0.03

95 98 47.5 0.05

95 95 19.0 0.05

95 90 9.5 0.06

95 85 6.3 0.06

95 80 4.8 0.06

95 75 3.8 0.07

95 70 3.2 0.07

90 98 45.0 0.10

90 95 18.0 0.11

90 90 9.0 0.11

90 85 6.0 0.12

90 80 4.5 0.13

90 75 3.6 0.13

90 70 3.0 0.14

85 98 42.5 0.15

85 95 17.0 0.16

85 90 8.5 0.17

85 85 5.7 0.18

85 80 4.3 0.19

85 75 3.4 0.20

85 70 2.8 0.21

80 98 40.0 0.20

80 95 16.0 0.21

80 90 8.0 0.22

80 85 5.3 0.24

80 80 4.0 0.25

80 75 3.2 0.27

80 70 2.7 0.29

75 98 37.5 0.26

75 95 15.0 0.26

75 90 7.5 0.28

75 85 5.0 0.29

75 80 3.8 0.31

75 75 3.0 0.33

75 70 2.5 0.36

* Pos = positive; Neg = negative.

Table 4–Hypothetical Results on 1,000 Patients Who

Have Undergone a Polysomnogram (AHI) and a

Portable Monitor Test (RDI) *

[greater than

or equal to]

RDI 10 ([dagger]) < 10 ([double dagger])

[greater than or equal to] 40 178 820-39 129 31

10-19 53 3

5-9 27 189

< 5 13 339

400 600

* Values given as No. of patients, unless otherwise indicated.

([dagger]) Positive for sleep apnea.

([double dagger]) Negative for sleep apnea.

Table 5–The Effect on Sensitivity, Specificity, Positive

and Negative Predictive Values and False-Negative and

False-Positive Results of Changing the RDI Threshold

for a Positive Result

AHI

[greater than or

RDI equal to] 10 * < 10 ([dagger])

[greater than or equal to]40 ([double dagger]) ([section]) 178 8

< 40 ([parallel]) 222 592

Total 400 600

[greater than or equal to]20 ([double dagger]) ([paragraph]) 307 39

< 20 ([parallel]) 93 561

Total 400 600

[greater than or equal to]10 ([double dagger]) (#) 360 72

< 10 ([parallel]) 40 528

Total 400 600

[greater than or equal to]5 ([double dagger]) ** 387 261

< 5 ([parallel]) 13 339

Total 400 600

RDI Total LR

[greater than or equal to]40 ([double dagger]) ([section]) 186 44.5/1.3 = 34.2

< 40 ([parallel]) 814 54.5/98.7 = 0.55

Total 1,000

[greater than or equal to]20 ([double dagger]) ([paragraph]) 346 76.8/6.5 = 11.8

< 20 ([parallel]) 654 24.2/93.5 = 0.26

Total 1,000

[greater than or equal to]10 ([double dagger]) (#) 432 90.0/12.0 = 7.5

< 10 ([parallel]) 568 10.0/88.0 = 0.11

Total 1,000

[greater than or equal to]5 ([double dagger]) ** 648 96.8/43.5 = 2.2

< 5 ([parallel]) 352 3.2/56.5 = 0.06

Total 1,000

* Positive for sleep apnea.

([dagger]) Negative for sleep apnea.

([double dagger]) Positive result.

([section]) For RDI cutoff of 40: sensitivity, 178/400 (44.5%);

specificity, 592/600 (98.7%); positive predictive value,

178/186 (90.7%); negative predictive value. 592/81 (72.7%); patients

testing positive, 186/1,000 (18.6%) patients testing positive with

a false-positive result, 8/186 (4.3%); patients testing negative,

814/1,000 (81.4%); patients testing negative with a false-negative

result, 222/814 (27.3%).

([parallel]) Negative result.

([paragraph]) For RDI cutoff of 20: sensitivity, 307/400 (76.8%);

specificity, 561/600 (93.5%); positive predictive value, 307/346,

(88.7%); negative predictive value, 561/654 (85.8%); patients testing

positive, 346/1000 (34.6%); patients testing positive with a

false-positive result, 39/346 (11.3%): patients testing negative,

654/1,000 (65.4%); patients testing negative with a false-negative

result, 93/654 (14.2%).

(#) For RDI cutoff of 10: sensitivity, 360/400 (90.0%); specificity,

528/600 (88.0%); positive predictive value, 360/432 (83.3%); negative

predictive value, 528/568 (93.0%); patients testing positive,

432/1,000 (43.2%): patients testing positive with a false-positive

result, 72/432 (16.7%); patients testing negative, 568/10,110 (56.8%);

patients testing negative with a false-negative result, 40/568 (7.0%).

** For RDI cutoff of 5: sensitivity 387/400 (96.8%); specificity,

339/600 (56.5%); positive predictive value, 387/648 (59.7%); negative

predictive value, 339/352 (96.3%); patients testing positive,

648/1,000 (64.8%); patients testing positive with a false-positive

result, 261/648 (40.2%); patients testing negative, 352/1,000

(35.2%); patients testing negative with a false-negative result, 13/352

(3.7%).

Table 6–LRs for Each Level of RDI Result

AHI

[greater than or equal to 10] *

Patients,

RDI No. Proportion

[greater than or equal to] 40 178 178/400 = 0.44520-39 129 129/400 = 0.353

10-19 53 53/400 = 0.133

5-9 27 29/400 = 0.068

< 5 13 13/400 = 0.033

Total 400

AHI

< 10 ([dagger])

Patients,

RDI No. Proportion

[greater than or equal to] 40 8 8/600 = 0.01320-39 31 31/600 = 0.052

10-19 33 33/600 = 0.055

5-9 189 189/600 = 0.315

< 5 339 339/600 = 0.565

Total 600

RDI LR

[greater than or equal to] 40 0.445/0.013 = 34.220-39 0.323/0.052 = 6.21

10-19 0.133/0.055 = 2.42

5-9 0.069/0.315 = 0.21

< 5 0.033/0.565 = 0.06

Total

* Positive for sleep apnea.

([dagger]) Negative for sleep apnea.

Table 7–Effect of Using as RDI Threshold of 40 to

Define Patients With Sleep Apnea and an RDI

Threshold of 5 to Define Patients Without Sleep Apnea

AHI

[greater than

RDI or equal] to 10 * < 10 ([dagger])

[greater than or equal to] 40 178 8< 5 13 339

Total ([double dagger]) 191/400 347/600

RDI Total

[greater than or equal to] 40 186< 5 352

Total ([double dagger]) 538 ([section])/1,000

* Positive for sleep apnea.

([dagger]) Negative for sleep apnea.

([double dagger]) Values given as patients with a positive or

negative result/total No. of patients.

([section]) Of these, 462 had neither a positive nor a negative result.

Table 8–Effect of Using an RDI Threshold of 20 to

Define Patients With Sleep Apnea and an RDI

Threshold of 5 to Define Patients Without Sleep Apnea

AHI

[greater than

RDI or equal to] 10 * < 10 ([dagger])

[greater than or equal to] 20 (+ve) 307 39< 5 (+ve) 13 339

Total ([double dagger]) 320/400 378/600

RDI Total

[greater than or equal to] 20 (+ve)346

< 5 (+ve) 352

Total ([double dagger]) 685 ([section])/1,000

* Positive for sleep apnea.

([dagger]) Negative for sleep apnea.

([double dagger]) Values given as patients with a

positive or negative result/total No. of patients.

([section]) Of these, 302 had neither a positive nor a

negative result.

REFERENCES

(1) American Sleep Disorders Association. Practice parameters for the indications for polysomnography and related procedures: Polysomnography Task Force, American Sleep Disorders Association Standards of Practice Committee. Sleep 1997; 20:406-422

(2) Bland JM, Altman DG. Statistical methods for assessing agreement between two methods of clinical measurement. Lancet 1986; 1:307-310

(3) Streiner DL, Norman GR. Health measurement scales: a practical guide to their development. 2nd ed. New York, NY: Oxford University Press, 1995

(4) Sackett DL, Strauss SE, Richardson WS, et al. Evidence-based medicine: how to practice and teach EBM. 2nd ed. Edinburgh, Scotland, UK: Churchill Livingstone, 2000

(5) Fagan TJ. Nomogram for Bayes theorem [letter]. N Engl J Med 1975; 293:257

* From the Faculty of Medicine (Dr. Flemons), University of Calgary, Calgary, AB, Canada; and the Veterans Affairs Greater Los Angeles Healthcare System. (Dr. Littner), Sepulveda, CA.

Manuscript received May 1, 2003; revision accepted May 2, 2003.

Correspondence to: W. Ward Flemons, MD, Faculty of Medicine, University of Calgary, 1403 Twenty-Ninth St NW, Calgary, AB, Canada, T2N 2T9; e-mail: flemons@ucalgary.ca

COPYRIGHT 2003 American College of Chest Physicians

COPYRIGHT 2003 Gale Group